Ascent Pharma's Bcl-2 inhibitor APG-2575 shows strong potential in the treatment of relapsed and refractory CLL/SLL

A research and development company in the clinical stage dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases - Ascent Pharmaceuticals announced that the American Society of Clinical Oncology (ASCO) has announced Bcl-2 inhibitors on its official website today Summary of the first human trial of lisaftoclax (APG-2575) in the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other hematological malignancies
.

The latest progress of the research will be further demonstrated in the form of an oral report at the ASCO annual meeting to be held from June 4 to 8, 2021
.

“APG-2575 is the second Bcl-2 inhibitor in the world and the first domestic Bcl-2 inhibitor to see a clear effect
.

The summary of the research of Ascent Pharmaceuticals selected for the 2021 ASCO annual meeting is as follows (two studies on APG-115 are listed in another press release issued at the same time):

First-in-human study of lisaftoclax (APG-2575), a novel Bcl-2 inhibitor (Bcl-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs)

The first human trial of a new Bcl-2 inhibitor APG-2575 in the treatment of patients with R/R CLL and other HMs

Presentation format: Oral report
Abstract number: #7502
Time: Beijing time 2021.

• This first global phase I clinical study conducted in humans evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and maximum efficacy of APG-2575 in patients with R/R CLL and other HMs.
  Tolerable dose (MTD)/Recommended dose for phase II study (RP2D)
  
  

  Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC)

  APG-1252 combined with paclitaxel in the treatment of relapsed/refractory small cell lung cancer (R/R SCLC) multi-center phase Ib/II clinical study

  Display format: poster display
  Abstract number: #TPS8589
  Time: Beijing time 2021.

  
  6.
  4, 21:00 / US Eastern time 2021.
  
  
  • This is an open-label, multi-center Phase Ib/II study to evaluate the safety and preliminary efficacy of APG-1252 combined with paclitaxel in treated SCLC patients
    .
    
  • The study took 21 days as a cycle.
    APG-1252 was administered intravenously on days 1, 8 and 15, and paclitaxel was administered at a fixed dose of 80 mg/m2 on days 1 and 8
    .
    
    
  • The primary endpoints of the Phase Ib study are MTD and RP2D
    .
    The phase II study uses ORR as the primary endpoint.
    The Simon two-phase design will be used to evaluate the efficacy of this combination therapy.
    Other research endpoints include PK, progression-free survival and overall survival
    .
    
  • The study plans to recruit 58 patients
    .
    As of February 8, 2021, 15 patients have been enrolled
    .